KLB: A Potential Drug Target and Biomarker (G152831)

Target Name: KLB

NCBI ID: G152831

Content of Review Report on KLB Target / Biomarker

KLB

KLB: A Potential Drug Target and Biomarker

KLB (Beta-klotho), a protein that is expressed in various tissues throughout the body, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

KLB is a protein that is composed of two main regions: the N-terminus and the C-terminus. The N-terminus is responsible for the protein's basic structure and functions as a scaffold, while the C-terminus is involved in the protein's interactions with other molecules. The unique feature of KLB is its ability to form a beta-sheet, which is a type of protein structure that is known for its stability and flexibility.

Research has shown that KLB is involved in various cellular processes, including cell adhesion, migration, and invasion. It has also been shown to play a role in the regulation of cell growth, apoptosis, and inflammation. These functions make KLB a potential drug target for diseases that involve these processes, such as cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key challenges in studying KLB is its complex structure. Unlike many other proteins, KLB does not have a single, monomeric form. Instead, it forms a complex with other molecules, including nucleotides, proteins, and small molecules. This complexity makes it difficult to study the protein's function and determine how it interacts with other molecules. However, researchers have been able to use techniques such as biochemical assays and mass spectrometry to study the complex structure of KLB and its interactions with other molecules.

In addition to its potential as a drug target, KLB has also been identified as a potential biomarker for various diseases. Its complex structure and function make it an attractive target for diagnostic tests, such as mass spectrometry-based assays, that can detect changes in the protein's structure and activity in response to different conditions. For example, researchers have used KLB as a biomarker to study the effects of drugs on cancer cells, and have found that the protein's structure and activity can be affected by these drugs.

KLB's ability to form a beta-sheet is also a unique feature that makes it an attractive target for drug development. Beta-sheet structures are known for their stability and flexibility, which makes them difficult to target with small molecules. However, researchers have been able to develop small molecules that can interact with KLB's beta-sheet and modulate its activity. This has led to a new era of drug development for diseases that are resistant to traditional therapies.

In conclusion, KLB is a protein that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and function make it an attractive target for researchers to study and develop new treatments. While more research is needed to fully understand the protein's role in these diseases, its potential as a drug and biomarker is a promising area of research.

Protein Name: Klotho Beta

Functions: Contributes to the transcriptional repression of cholesterol 7-alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis. Probably inactive as a glycosidase. Increases the ability of FGFR1 and FGFR4 to bind FGF21 (By similarity)

The "KLB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets